Skip to main content
JDRS · Open access journal

Case Report · Open access

Endobronchial pulmonary metastasis in malignant tenosynovial giant cell tumor: A rare cause of central airway obstruction

PDF Cite this article

Ipek Çalık

Department of Pulmonology, Başakşehir Çam ve Sakura City Hospital, İstanbul, Türkiye

ORCID: 0000-0001-7373-8581

Canberk Canayakın

Department of Pulmonology, Başakşehir Çam ve Sakura City Hospital, İstanbul, Türkiye

ORCID: 0009-0006-5856-0264

Şule Kevser Dursun

Department of Pathology, Başakşehir Çam ve Sakura City Hospital, İstanbul, Türkiye

ORCID: 0000-0003-2274-6869

Nur Büyükpınarbaşılı

Department of Pathology, Başakşehir Çam ve Sakura City Hospital, İstanbul, Türkiye

ORCID: 0000-0002-1784-6665

Mehmet Akif Özgül

Department of Pulmonology, Başakşehir Çam ve Sakura City Hospital, İstanbul, Türkiye

ORCID: 0000-0003-1110-6823

Abstract

Tenosynovial giant cell tumor (TGCT) is a rare mesenchymal neoplasm arising from the synovium, tendon sheath, or bursa. Although the localized and diffuse forms of TGCT are typically considered benign, malignant TGCT characterized by marked histologic atypia and increased mitotic activity may exhibit aggressive clinical behavior. Pulmonary metastasis from malignant TGCT is rare and, in previously reported cases, pulmonary involvement has predominantly been described as parenchymal nodules or pleural lesions. In this article, we describe a rare case of endobronchial pulmonary metastasis occurring approximately 72 months after the initial diagnosis of malignant TGCT originating from the tendon sheath of the knee.

Declarations

Author Contributions

I.C.: Idea/concept, design; M.A.O.: Control/supervision, analysis and/or interpretation; C.C., S.K.D., N.B.: Data collection and/or processing; I.C., C.C.: Literature review, writing the article; M.A.O.: Critical review; I.C., C.C., S.K.D., N.B.: References and fundings; S.K.D., N.B., M.A.O.: Materials.

Conflict of Interest

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Financial Disclosure

The authors also acknowledge the institutional support provided by the Department of Pulmonology.

Acknowledgments

The authors thank the interventional pulmonology nurses and technical staff of Basaksehir Cam ve Sakura City Hospital for their valuable assistance during the bronchoscopic procedure.

Data Sharing Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

AI Disclosure

The authors declare that artificial intelligence (AI) tools were not used, or were used solely for language editing, and had no role in data analysis, interpretation, or the formulation of conclusions. All scientific content, data interpretation, and conclusions are the sole responsibility of the authors. The authors further confirm that AI tools were not used to generate, fabricate, or ‘hallucinate’ references, and that all references have been carefully verified for accuracy.

References

  1. Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, et al. Best clinical management of Tenosynovial Giant Cell Tumour (TGCT): A consensus paper from the community of experts. Cancer Treat Rev 2023;112:102491. DOI: 10.1016/j.ctrv.2022.102491.
  2. Mastboom MJL, Palmerini E, Verspoor FGM, RuetenBudde AJ, Stacchiotti S, Staals EL, et al. Surgical outcomes of patients with diffuse-type tenosynovial giantcell tumours: An international, retrospective, cohort study. Lancet Oncol 2019;20:877-86. DOI: 10.1016/S1470-2045(19)30100-7.
  3. Sikaria S, Heim-Hall J, Diaz EH, Williams R, Sankhala K, Laabs B, et al. Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor. Target Oncol 2014;9:73- 9. DOI: 10.1007/s11523-013-0267-8.
  4. Shaik AA, Panigrahi MK, Patro M, Sushmita V, Mishra P. Localized type tenosynovial giant cell tumor with metastases to lungs and pleura: A case report and literature review. J Med Case Rep 2024;18:452. DOI: 10.1186/s13256-024-04768-w.
  5. Bliss BO, Reed RJ. Large cell sarcomas of tendon sheath. Malignant giant cell tumors of tendon sheath. Am J Clin Pathol 1968;49:776-81. DOI: 10.1093/ajcp/49.6.776.
  6. Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 2012;118:1649-55. DOI: 10.1002/cncr.26409.
  7. Bertoni F, Unni KK, Beabout JW, Sim FH. Malignant giant cell tumor of the tendon sheaths and joints (malignant pigmented villonodular synovitis). Am J Surg Pathol 1997;21:153-63. DOI: 10.1097/00000478-199702000-00004.
  8. Li CF, Wang JW, Huang WW, Hou CC, Chou SC, Eng HL, et al. Malignant diffuse-type tenosynovial giant cell tumors: A series of 7 cases comparing with 24 benign lesions with review of the literature. Am J Surg Pathol 2008;32:587-99. DOI: 10.1097/PAS.0b013e318158428f.
  9. Al-Ibraheemi A, Ahrens WA, Fritchie K, Dong J, Oliveira AM, Balzer B, et al. Malignant tenosynovial giant cell tumor: The true “Synovial Sarcoma?” a clinicopathologic, immunohistochemical, and molecular cytogenetic study of 10 cases, supporting origin from synoviocytes.. Mod Pathol 2019;32:242-51. DOI: 10.1038/s41379-018-0129-0.
  10. Atik E, Özgür T, Kalaci A, Tuna B. Tenosynovial giant cell tumor in an unusual localization. Acta Orthop Traumatol Turc 2013;47:139-41. DOI: 10.3944/aott.2013.2773.